natgillin/translations-raw huggingface dataset:
In vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (COX-2) to a greater extent than cyclooxygenase-1 (COX-1). 
In vitro i in vivo ispitivanjima dokazano je da meloxicam inhibira ciklooksigenazu-2 (COX-2) više nego ciklooksigenazu-1 (COX-1).
Pull the plunger out until the black on the plunger corresponds to your dog's bodyweight in kilograms. 
Izvucite klip do trenutka kad crni dio odgovara tjelesnoj težini vašeg psa u kilogramima.
Approximately 97 % of meloxicam is bound to plasma proteins. 
Oko 97% meloxicama veže se na proteine u plazmi.
Meloxicam is metabolised to an alcohol, an acid derivative and to several polar metabolites. 
Meloxicam se metabolizira u alkohol, derivate kiselina i nekoliko polarnih metabolita.
To be administered with food. 
Primijeniti s hranom.
Meloxicam is predominantly found in plasma and is also a major biliary excretion product whereas urine contains only traces of the parent compound. 
Meloxicam se predominantno nalazi u plazmi i također je glavni bilijarni proizvod izlučivanja, dok urin sadrži samo tragove osnovnog spoja.
Keep out of the reach and sight of children. 
Čuvati izvan pogleda i dosega djece.
After each dose, the tip of the syringe should be wiped and the bottle cap screwed back on tightly. 
Nakon svake doze, vrh štrcaljke treba obrisati, a čep boce snažno uvrnuti.
Meloxivet must not be administered in conjunction with other NSAIDs or glucocorticosteroids. 
Meloxivet se ne smije primijeniti u vezi s NSAID-ima ili glukokortikosteroidima.
For longer term treatment once clinical response has been observed (after 4 or more days), the dose of Meloxivet can be adjusted to the lowest effective individual dose reflecting that the degree of pain and inflammation associated with chronic musculo-skeletal disorders may vary over time. 
Za dugotrajna liječenja nakon što je uočen klinički odgovor (nakon 4 ili više dana), doza lijeka Meloxivet može se prilagoditi na najnižu pojedinačnu djelotvornu dozu što će se odraziti na činjenicu da stupanj boli i upale povezani s mišićno-koštanim poremećajima mogu varirati s vremena na vrijeme.
Approximately 75 % of the administered dose of meloxicam is eliminated via faeces and the remainder via urine. 
Oko 75% primijenjene doze lijeka meloxicam eliminira se putem izmeta, a ostatak putem urina.
When the product is used according to the recommended dosage regime, steady state concentrations of meloxicam in plasma are reached on the second day of treatment. 
Kad se proizvod primjenjuje u skladu s preporučenim režimom doziranja, stabilna stanja koncentracije meloxicama u plazmi postižu se u drugom danu liječenja.
Marketing authorisation holder: Eli Lilly and Company Limited Elanco Animal Health Lilly House, Priestley Road Basingstoke 
Nositelj odobrenja za stavljanje u promet: Eli Lilly and Company Limited Elanco Animal Health Lilly House, Priestley Road Basingstoke
The safety of the veterinary medicinal product has not been established during pregnancy and lactation (see section 4.3). 
4.7 Primjena tijekom graviditeta, laktacije ili nesenja Sigurnost veterinarsko-medicinskog proizvoda nije ustanovljena za vrijeme graviditeta i laktacije (vidi dio 4.3).
Meloxicam is completely absorbed following oral administration and maximal plasma concentrations are obtained after approximately 6.1 hours. 
Apsorpcija Meloxicam se apsorbira u potpunosti prilikom oralne primjene, a maksimalne koncentracije u plazmi postižu se nakon otprilike 6,1 sati.
Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) of the oxicam class which acts by inhibition of prostaglandin synthesis, thereby exerting anti-inflammatory, analgesic, anti-exudative and antipyretic effects. 
Meloxicam je nesteroidni protuupalni lijek (NSAID) oksikam klase koji djeluje inhibirajući sintezu prostaglandina i na taj način ima protuupalni, analgetički, antieksudativni i antipiretički učinak.
In very rare cases haemorrhagic diarrhoea, haematemisis, gastrointestinal ulceration and elevated liver enzymes have been reported. 
U vrlo rijetkim slučajevima prijavljene su hemoragijske dijareje, hematemeze, gastrointestinalne ulceracije i povišeni enzimi jetre.
If adverse reactions occur, treatment should be discontinued and the advice of the veterinarian should be sought. 
Ako se pojave nuspojave, liječenje treba prekinuti i potražiti savjet veterinara.
Do not use after the expiry date stated on the label and carton after EXP. 
Ne koristite veterinarsko-medicinski proizvod poslije isteka roka valjanosti naznačenog na etiketi i kutiji poslije EXP.
Other NSAIDs, diuretics, anticoagulants, aminoglycoside antibiotics and substances with high protein binding may compete for binding and thus lead to toxic effects. 
Ostali NSAID-i, diuretici, antikoagulanti, aminoglikozoidi i tvari s visokim stupnjem vezanja proteina mogu konkurirati u vezanju i tako dovesti do toksičnih efekata.
By pushing the plunger in empty the contents of the syringe onto the food. 
Pritiskanjem klipa ispraznite sadržaj štrcaljke u hranu.
Pre- treatment with anti-inflammatory substances may result in additional or increased adverse reactions and accordingly a treatment-free period with such veterinary medicinal products should be observed for at least 24 hours before commencement of treatment. 
Prethodno liječenje protuupalnim tvarima može rezultirati dodatnim ili povećanim nuspojavama pa je prema tome potrebno razdoblje bez primjene takvih veterinarsko-medicinskih proizvoda barem 24 sata prije početka liječenja.
There is a linear relationship between the dose of meloxicam administered and plasma concentration observed in the therapeutic dose range. 
Postoji linearna veza između primijenjene doze meloxicama i koncentracije u plazmi uočene u rasponu terapijskih doza.
In case of overdose symptomatic treatment should be initiated. 
U slučaju predoziranja, potrebno je započeti simptomatsko liječenje.
Meloxicam is eliminated with a half-life of 24 hours. 
Poluvrijeme života za Meloxicam je 24 sata.
Initial treatment is a single dose of 0.2 mg meloxicam/kg body weight on the first day. 
Početno liječenje je jednokratna doza od 0,2 mg meloxicama/kg tjelesne težine prvog dana.
The suspension has to be given with the measuring syringes provided in the package of the 30 ml and 150 ml pack size or with one of the two measuring syringes provided in the package of the 10 ml pack size. 
Suspenziju je potrebno primijeniti štrcaljkom za mjerenje priloženom u pakovanju od 30 ml i 150 ml ili s jednom od dvije štrcaljke za mjerenje koje se nalaze u pakovanju od 10 ml.
Particular care should be taken with regard to the accuracy of dosing. 
Poseban oprez neophodan je prilikom određivanja točnosti doze.
The suspension has to be given with the measuring syringe provided in the package. 
Suspenziju je potrebno primijeniti štrcaljkom za mjerenje priloženom u pakovanju.
1 mg For a full list of excipients, see section 6.1. 
Potpuni popis pomoćnih tvari vidi u odjeljku 6.1.
The syringe fits onto the bottle and has a kg-body weight scale which corresponds to the maintenance dose (i.e. 0.1 mg meloxicam/kg body weight). 
Štrcaljka se namjesti na bocu i sadrži skalu kg-tjelesne težine koji odgovara dozi održavanja (tj. 0,1 mg meloxicama/kg tjelesne težine).
Citric acid monohydrate Sodium hydroxide Purified water 
Monohidrat limunove kiseline Natrijev hidroksid Deionizirana voda
To a minor extent it also inhibits collagen-induced thrombocyte aggregation. 
U manjem obimu također sprječava kumuliranje trombocita izazvano kolagenom.
SPECIAL STORAGE CONDITIONS This veterinary medicinal product does not require any special storage conditions. 
11. POSEBNI UVJETI ČUVANJA Ovaj veterinarsko-medicinski proizvod ne zahtijeva nikakve posebne uvijete čuvanja.
4.11 Withdrawal period(s) Not applicable. 
4.11 Karencija Nije primjenjivo.
Treatment is to be continued once daily by oral administration (24 hour intervals) at a maintenance dose of 0.1 mg meloxicam/kg body weight. 
Liječenje se nastavlja jednom dnevno oralnom primjenom (24-satni intervali) u dozama održavanja od 0,1 mg meloxicama/kg tjelesne težine.
MANUFACTURER'S BATCH NUMBER Lot 
17 BROJ PROIZVODNE SERIJE PROIZVOĐAČA
The treatment-free period, however, should take into account the pharmacological properties of veterinary medicinal products used previously. 
Razdoblje bez liječenja, u svakom slučaju, treba uzeti u obzir farmakološka svojstva prethodno primijenjenog veterinarsko-medicinskog proizvoda.
The volume of distribution is 0.3 1/kg. 
Opseg raspodjele je 0,3 l/kg.
The suspension of the 10 ml pack size could be administered using the smallest syringe for dogs less than 8 kg body weight (one graduation corresponding to 0.5 kg of body weight) or the largest syringe for dogs over than 8 kg body weight (one graduation corresponding to 2.0 kg of body weight). 
kg tjelesne težine (jedna gradacija odgovara 0,5 kg tjelesne težine) ili najvećom štrcaljkom za pse preko 8 kg tjelesne težine (jedna gradacija odgovara 2,0 kg tjelesne težine).
Do not use in dogs suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders. 
Ne primjenjivati na psima koji pate od probavnih poremećaja kao što su iritacija i hemoragija, oštećenja jetrenih, srčanih ili bubrežnih funkcija i hemoragijskih poremećaja.
Turn the bottle right way up and with a twisting movement separate the dosing syringe from the bottle. 
Okrenite bocu u uspravni položaj i zakretanjem štrcaljke izvucite štrcaljku iz boce.
Attach the dosing syringe to the bottle by gently pushing the end onto the top the bottle 
Postavite štrcaljku za doziranje na bocu na način da lagano gurnete njen vrh u vrh boce.
INDICATION(S) Acute and chronic musculo-skeletal disorders. 
Akutni i kronični mišićno-koštani poremećaji.
Push down and unscrew bottle top. 
Pritisnite prema dolje i odvrnite vrh boce.
Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with local requirements. 
Bilo koji neupotrebljeni veterinarsko-medicinski proizvod ili otpadni materijali dobiveni primjenom tih veterinarsko-medicinskih proizvoda trebaju se odlagati u skladu s lokalnim propisima.
Microcrystalline cellulose Xxanthan gum Carboxymethylcellulose Sodium benzoate Sodium saccharinate 
Mikrokristalna celuloza Xxanthan guma Karboksimetilceluloza Natrijev benzoat
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton box for bottle 10, 30 and 150 ml 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU KARTONSKA KUTIJA ZA BOCU OD 10, 30 I 150 ML
White to yellowish opaque suspension. 
Neprozirna suspenzija bijele do žućkaste boje.
PHARMACEUTICAL FORM Oral suspension. 
Oralna suspenzija.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there is a potential risk of renal toxicity. 
Izbjegavajte primjenu na dehidriranim, hipovolemičnim ili hipotenzivnim psima, jer postoji rizik od bubrežne toksičnosti.
INDICATION(S) Alleviation of inflammation and pain in both acute and chronic musculo-skeletal disorders in dogs. 
Ublažavanje upale i bolova kod akutnih i kroničnih mišićno-koštanih poremećaja kod pasa.
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE Label bottle 150 ml 
PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKOVANJU ETIKETA BOCA 150 ML
SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY 
12. POSEBNE MJERE OPREZA PRI ODLAGANJU NEUPOTRJEBLJENIH PROIZVODA ILI OTPADNIH MATERIJALA, AKO IH IMA
Shake bottle well. 
Dobro protresti bocu.
Do not use in pregnant or lactating dogs. 
Ne primjenjivati na gravidnim kujama ili kujama dojiljama.
Do not administer Meloxivet: - if your dog is pregnant or during lactation - if your dog is suffering from gastrointestinal disorders such as irritation and haemorrhage, impaired hepatic, cardiac or renal function and haemorrhagic disorders - if your dog is hypersensitive (allergic) to the active substance or to any of the other ingredients. 
- ako vaš pas boluje od probavnih poremećaja kao što su iritacija i hemoragija, oštećenja jetrenih, srčanih ili bubrežnih funkcija i hemoragijskih poremećaja - ako je vaš pas preosjetljiv na djelatnu tvar ili na bilo koju pomoćnu tvar - ako je vaš pas mlađi od 6 tjedana.
PARTICULARS TO APPEAR ON THE OUTER PACKAGE Carton box for bottle 10 and 30 ml 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKOVANJU KARTONSKA KUTIJA ZA BOCU OD 10 I 30 ML
QUALITATIVE AND QUANTITATIVE COMPOSITION One ml contains 
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNIH
Turn the bottle syringe upside down. 
Okrenite naopako bocu i štrcaljku.
Pharmacotherapeutic group: Anti-inflammatory and antirheumatic products, non-steroids (oxicams), ATCvet code: QM01AC06 
Farmakoterapijska grupa: Nesteroidni protuupalni i antireumatski proizvodi (oksikami).
EXPIRY DATE EXP 
ROK VALJANOSTI EXP {mjesec/godina}
People with known hypersensitivity to NSAIDs should avoid contact with the veterinary medicinal product. 
Ljudi s poznatom preosjetljivošću na NSAID-e ili bilo koju pomoćnu tvar trebaju izbjegavati kontakt s veterinarsko-medicinskim proizvodom.
People with known hypersensitivity to Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should avoid contact with the veterinary medicinal product. 
Osobe s poznatom preosjetljivošću na nesteroidne protuupalne lijekovi (NSAID) moraju izbjegavati kontakt s ovim veterinarsko-medicinskim proizvodom.
STATEMENT OF ACTIVE AND OTHER SUBSTANCES Each ml contains: 
I DRUGIH TVARI Svaki ml sadrži:
ROUTE(S) OF ADMINISTRATION Oral use. 
PUT(EVI) PRIMJENE Oralna primjena.
Typical adverse reactions of NSAIDs such as loss of appetite, vomiting, diarrhoea, faecal occult blood, lethargy and renal failure have occasionally been reported. 
Prijavljene su povremene tipične nuspojave NSAID-a kao što su gubitak teka, povraćanje, dijareja, nevidljivo postojanje krvi u stolici, letargija i zatajenje bubrega.
QUANTITY OF THE ACTIVE SUBSTANCE(S) Meloxicam 0.5 mg/ml 
Meloxicam 0,5 mg/ml
QUANTITY OF THE ACTIVE SUBSTANCE(S) Meloxicam 1.5 mg/ml 
Meloxicam 1,5 mg/ml
30 ml and 150 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and clear polypropylene dosing syringe. 
Pakovanje od 30 ml i 150 ml: boca boje jantara (tip III) s polipropilenskim čepom za zaštitu od otvaranja za djecu, polietilenskim umetkom i prozirnom polipropilenskom štrcaljkom za doziranje.
NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxivet 1.5 mg/ml oral suspension for dogs 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Meloxivet 1,5 mg/ml oralna suspenzija za pse
NAME OF THE VETERINARY MEDICINAL PRODUCT Meloxivet 0.5 mg/ml oral suspension for dogs 
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA Meloxivet 0,5 mg/ml oralna suspenzija za pse
Dosage 
KARENCIJA
Name and address of the manufacturer(s) responsible for batch release 
PROIZVOĐAČ ODGOVORAN ZA PUŠTANJE SERIJE U PROMET Naziv i adresa proizvođača odgovornog(ih) za puštanje serije u promet
For animal treatment only - to be supplied only on veterinary prescription. 
Veterinarsko-medicinski proizvod se izdaje na veterinarski recept.
MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE 
Nositelj odobrenja za proizvodnju odgovoran za puštanje serije u promet: Lusomedicamenta S.A.
MARKETING AUTHORISATION NUMBER(S) EU/2/07/077/001 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/07/077/001
PACKAGE LEAFLET FOR: Meloxivet 1.5 mg/ml oral suspension for dogs 
UPUTA O VMP ZA: Meloxivet 1,5 mg/ml oralna suspenzija za pse
SPECIAL WARNING(S), IF NECESSARY Do not use in pregnant or lactating dogs 
KONTRAINDIKACIJE Nemojte primjenjivati Meloxivet: - ako je vaša kuja gravidna ili za vrijeme laktacije
PACKAGE LEAFLET FOR: Meloxivet 0.5 mg/ml oral suspension for dogs 
UPUTA O VMP ZA: Meloxivet 0,5 mg/ml oralna suspenzija za pse
MARKETING AUTHORISATION NUMBER(S) EU/2/07/077/003 
BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/07/077/003
MARKETING AUTHORISATION NUMBER(S) EU/2/07/077/005 
16. BROJ(EVI) ODOBRENJA ZA STAVLJANJE U PROMET EU/2/07/077/005
30 ml presentation: amber glass bottle (type III) with polypropylene child resistant closure, polyethylene insert and an amber polypropylene dosing syringe. 
Pakovanje od 30 ml: boca boje jantara (tip III) s polipropilenskim čepom za zaštitu od otvaranja za djecu, polietilenskim umetkom i polipropilenskom štrcaljkom za doziranje boje jantara.
MARKETING AUTHORISATION NUMBER(S) 
INDIKACIJA(E)
Absorption 
DODATAK
D. STATEMENT OF THE MRLs Not applicable. 
KARENCIJA Nije primjenjivo.
THE WORDS “KEEP OUT OF THE REACH AND SIGHT OF CHILDREN” Keep out of the reach and sight of children. 
14. RIJEČI „ČUVATI IZVAN POGLEDA
Pack size bottle (HDPE) 30 tablets bottle (HDPE) 90 (3 x 30) tablets 
Kroz usta bočica (HDPE) 90 (3 x 30) tableta
This may lead to increased procedural complications during the operation. 
To može dovesti do povećanja proceduralnih komplikacija tijekom operacije.
03410 Saint Victor France 
03410 Saint Victor Francuska
You may take your capsule later the same day if you have forgotten to take it earlier. 
Možete uzeti kapsulu kasnije istog dana ukoliko ste je zaboravili uzeti ranije.
It does not distribute into blood cells. 
Ne distribuira se u krvne stanice.
The absolute bioavailability is approximately 32%. 
Apsolutna bioraspoloživost iznosi približno 32%.
Do not give this medicine to children and adolescents below 18 years since there is no relevant indication for this age group. 
Nemojte davati ovaj lijek djeci i adolescentima u dobi manjoj od 18 godina, budući da u toj dobnoj skupini ne postoji odgovarajuća indikacija.
The observed effect was reversible. 
Primijećeni učinak bio je reverzibilan.
Tell your doctor in particular, if you take: 
Obavijestite svog liječnika osobito ako uzimate:
If it is almost time for the next dose, skip the dose you missed. 
Ako je uskoro vrijeme za sljedeću dozu, preskočite dozu koju ste propustili uzeti.
• Difficulties in getting or keeping an erection 
• poteškoće s postizanjem ili održavanjem erekcije
If you have taken more than one capsule, inform your doctor as soon as possible. 
Ako ste uzeli više od jedne kapsule, obavijestite čim prije svog liječnika.
This change is clinically not relevant and no dose adjustment is required. 
Ova promjena nije klinički važna i nije potrebno prilagođavati dozu.
Please inform your doctor if you are planning to have children. 
Molimo obavijestite liječnika ukoliko planirate imati djecu.
If you are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. 
Ako planirate imati dijete, od svog liječnika ili ljekarnika zatražite savjet prije nego uzmete ovaj lijek.
Food decreases Cmax by approximately 30%, increases tmax by approximately 1 hour and has little effect on AUC. 
Hrana smanjuje Cmax za približno 30%, povećava tmax za približno 1 sat i ima malo učinka na AUC.
• Decreased sexual drive 
• smanjeni spolni nagon
The possible side effects are listed below: 
Moguće nuspojave navedene su ispod:
10 hard capsules 20 hard capsules 30 hard capsules 50 hard capsules 90 hard capsules 100 hard capsules 
10 tvrdih kapsula 20 tvrdih kapsula 30 tvrdih kapsula 50 tvrdih kapsula 90 tvrdih kapsula 100 tvrdih kapsula
Difference (95% CI) vs placebo 
Razlika (95% CI) u odnosu na placebo
Discontinuing treatment with an α1-blocker 1-2 weeks prior to cataract surgery has been recommended, but the benefit and duration of stopping the therapy prior to cataract surgery has not yet been established. 
Preporučuje se prekid liječenja α1-blokatorom 1-2 tjedna prije operacije katarakte, ali korist i trajanje prekida terapije prije operacije katarakte još nije utvrđena.
• Dizziness, including dizziness when standing up (see also above, in this section) 
• omaglica, uključujući omaglicu pri ustajanju (vidjeti također gore, u istom ovom dijelu)
The capsule should be taken with food, preferably at the same time every day. 
Kapsulu je potrebno uzeti s hranom, po mogućnosti svaki dan u isto vrijeme.
The specialist can take appropriate precautions with respect to medicine and surgical techniques to be used. 
Specijalist može poduzeti odgovarajuće mjere opreza s obzirom na lijek i kiruršku tehniku koja će se koristiti.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, carcinogenic, mutagenic and teratogenic potential. 
Neklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, kancerogenosti, mutagenosti i teratogenosti.
Silodosin has not been evaluated in patients less than 18 years of age. 
Silodozin se nije ispitao u bolesnika mlađih od 18 godina.
Packs of 10, 20, 30, 50, 90, 100 capsules. 
Pakiranja od 10, 20, 30, 50, 90 i 100 kapsula.
Silodosin Placebo 
Silodozin Placebo
* p < 0.001 vs Placebo; ° p = 0.002 vs Placebo 
* p < 0,001 u odnosu na placebo; ° p = 0,002 u odnosu na placebo
In vitro data indicate that silodosin does not have the potential to inhibit or induce cytochrome P450 enzyme systems. 
In vitro podaci pokazuju da silodozin nema potencijal inhibirati ili inducirati sustave enzima citokroma P450.
Take the capsule always with food, preferably at the same time every day. 
Uvijek uzmite kapsulu s hranom, po mogućnosti svaki dan u isto vrijeme.
Baseline value (± SD) 
Početna vrijednost (± SD)
• a more frequent need to pass water, even at night. 
• učestala potreba za mokrenjem, čak i noću.
Orthostatic hypotension may occasionally lead to syncope (see section 4.4). 
Ortostatska hipotenzija može povremeno dovesti do sinkope (vidjeti dio 4.4).
At the first signs of orthostatic hypotension (such as postural dizziness), the patient should sit or lie down until the symptoms have disappeared. 
Pri prvim znakovima ortostatske hipotenzije (kao što je posturalna omaglica), bolesnik treba sjesti ili leći dok simptomi ne nestanu.
The incidence of orthostatic hypotension in placebo-controlled clinical studies was 1.2% with silodosin and 1.0% with placebo. 
Incidencija ortostatske hipotenzije u placebom kontroliranim kliničkim ispitivanjima bila je 1,2% uz silodozin i 1,0% uz placebo.
Should overdose of silodosin lead to hypotension, cardiovascular support has to be provided. 
Ako predoziranje silodozinom dovede do hipotenzije, mora se pružiti kardiovaskularna potpora.
In total, 1,581 patients have received silodosin at a dose of 8 mg once daily, including 961 patients exposed for at least 6 months and 384 patients exposed for 1 year. 
Ukupno je 1581 bolesnik primio silodozin u dozi od 8 mg jedanput na dan, uključujući 961 bolesnika izloženog najmanje 6 mjeseci i 384 bolesnika izloženih 1 godinu.
Silodosin has a volume of distribution of 0.81 L/kg and is 96.6% bound to plasma proteins. 
Silodozin ima volumen distribucije od 0,81 l/kg i 96,6% je vezan na proteine plazme.
• Abnormal results of liver function tests 
• abnormalni rezultati pretraga funkcije jetre
Exposure to silodosin and its main metabolites does not change significantly with age, even in subjects of age over 75 years. 
Starije osobe Izloženost silodozinu i njegovim glavnim metabolitima ne mijenja se značajno s dobi, čak niti u ispitanika starijih od 75 godina.
Results from this study should be interpreted with caution, since enrolled patients had normal biochemistry values, indicating normal metabolic function, and they were classified as having moderate liver impairment based on ascites and hepatic encephalopathy. 
Rezultate ovog ispitivanja treba tumačiti s oprezom, budući da su uključeni bolesnici imali normalne biokemijske vrijednosti koje su ukazivale na normalne metaboličke funkcije, a klasificiralo ih se kao da imaju umjereno oštećenje funkcije jetre na temelju ascitesa i hepatičke encefalopatije.
Consequently, the concomitant use of other α-adrenoreceptor antagonists is not recommended. 
Posljedično tome, ne preporučuje se istovremena primjena drugih antagonista α-adrenergičkih receptora.
Digital rectal examination and, when necessary, determination of prostate specific antigen (PSA) should be performed before treatment and at regular intervals afterwards. 
Digitorektalni pregled i, po potrebi, određivanje antigena specifičnog za prostatu (PSA) potrebno je napraviti prije liječenja i ponavljati u redovitim vremenskim razmacima nakon toga.